Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

ClinicalTrials.gov ID: NCT00335374

Public ClinicalTrials.gov record NCT00335374. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial

Study identification

NCT ID
NCT00335374
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Solvay Pharmaceuticals
Industry
Enrollment
202 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
30 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2007
Primary completion
Aug 31, 2008
Completion
Oct 31, 2008
Last update posted
Feb 5, 2009

2007 – 2008

United States locations

U.S. sites
14
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
419 Birmingham Alabama — —
413 Oceanside California — —
408 Oxnard California — —
422 New Haven Connecticut — —
403 Boca Raton Florida — —
411 Sarasota Florida — —
421 Augusta Georgia — —
410 Fort Wayne Indiana — —
417 Lexington Kentucky — —
405 Boston Massachusetts — —
420 Boston Massachusetts — —
406 Minneapolis Minnesota — —
412 Raleigh North Carolina — —
Site 402 Dayton Ohio — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 61 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00335374, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 5, 2009 · Synced Sep 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00335374 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →